[go: up one dir, main page]

RU2008101365A - Композиции и способы диагностики и лечения опухоли - Google Patents

Композиции и способы диагностики и лечения опухоли Download PDF

Info

Publication number
RU2008101365A
RU2008101365A RU2008101365/13A RU2008101365A RU2008101365A RU 2008101365 A RU2008101365 A RU 2008101365A RU 2008101365/13 A RU2008101365/13 A RU 2008101365/13A RU 2008101365 A RU2008101365 A RU 2008101365A RU 2008101365 A RU2008101365 A RU 2008101365A
Authority
RU
Russia
Prior art keywords
antibody
seq
protein
tumor
sequence
Prior art date
Application number
RU2008101365/13A
Other languages
English (en)
Other versions
RU2430112C2 (ru
Inventor
Марк ДЕННИС (US)
Марк ДЕННИС
Уилльям МАЛЛЕТ (US)
Уилльям МАЛЛЕТ
Пол ПОЛЕЙКИС (US)
Пол ПОЛЕЙКИС
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2008101365A publication Critical patent/RU2008101365A/ru
Application granted granted Critical
Publication of RU2430112C2 publication Critical patent/RU2430112C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

1. Выделенное антитело, содержащее по меньшей мере одну HVR-последовательность, выбранную из группы, включающей: ! (а) последовательность HVR-L1, выбранную из одной из последовательностей, представленных в SEQ ID NO:14-34; ! (б) последовательность HVR-L2, выбранную из одной из последовательностей, представленных SEQ ID NO:35-58; ! (в) последовательность HVR-L3, выбранную из одной из последовательностей, представленных в SEQ ID NO:59-73; ! (г) последовательность HVR-H1, выбранную из одной из последовательностей, представленных в SEQ ID NO:74-93; ! (д) последовательность HVR-H2, выбранную из одной из последовательностей, представленных в SEQ ID NO:94-112; и ! (е) последовательность HVR-H3, выбранную из одной из последовательностей, представленных в SEQ ID NO:113-118. ! 2. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193. ! 3. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197. ! 4. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193, и последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197. ! 5. Антитело по п.1, представляющее собой фрагмент антитела. ! 6. Антитело по п.1, представляющее собой химерное или гуманизированное антите�

Claims (36)

1. Выделенное антитело, содержащее по меньшей мере одну HVR-последовательность, выбранную из группы, включающей:
(а) последовательность HVR-L1, выбранную из одной из последовательностей, представленных в SEQ ID NO:14-34;
(б) последовательность HVR-L2, выбранную из одной из последовательностей, представленных SEQ ID NO:35-58;
(в) последовательность HVR-L3, выбранную из одной из последовательностей, представленных в SEQ ID NO:59-73;
(г) последовательность HVR-H1, выбранную из одной из последовательностей, представленных в SEQ ID NO:74-93;
(д) последовательность HVR-H2, выбранную из одной из последовательностей, представленных в SEQ ID NO:94-112; и
(е) последовательность HVR-H3, выбранную из одной из последовательностей, представленных в SEQ ID NO:113-118.
2. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193.
3. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197.
4. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193, и последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197.
5. Антитело по п.1, представляющее собой фрагмент антитела.
6. Антитело по п.1, представляющее собой химерное или гуманизированное антитело.
7. Антитело по п.1, конъюгированное с ингибирующим рост агентом.
8. Антитело по п.1, конъюгированное с цитотоксическим агентом.
9. Антитело по п.8, в котором цитотоксический агент выбран из группы, включающей токсины, антибиотики, радиоактивные изотопы или нуклеолитические ферменты.
10. Антитело по п.8, в котором цитотоксический агент представляет собой токсин.
11. Антитело по п.10, в котором токсин выбран из группы, включающей майтансиноид и калихеамицин.
12. Антитело по п.10, в котором токсин представляет собой майтансиноид.
13. Антитело по п.1, которое продуцируется в бактериях.
14. Антитело по п.1, которое продуцируется в СНО-клетках.
15. Антитело по п.1, которое индуцирует гибель клетки, с которой оно связывается.
16. Антитело по п.15, где клетка представляет собой клетку рака яичника.
17. Антитело по п.1, которое несет обнаруживаемую метку.
18. Выделенное антитело, которое содержит по меньшей мере один из гипервариабельных участков любого антитела, продуцируемого любой из линий клеток гибридомы, представленных в таблице 11.
19. Моноклональное антитело, продуцируемое любой из линий клеток гибридомы, представленных в таблице 11.
20. Клетка гибридомы, которая продуцирует моноклональное антитело, связывающееся в полипептидом ТАТ10772.
21. Способ идентификации первого антитела, которое связывается с антигенным эпитопом ТАТ10772, сшитым со вторым антителом, где второе антитело представляет собой любое из антител по пп.1, 18 или 19, заключающийся в том, что определяют способностью первого антитела блокировать связывание второго антитела с полипептидом ТАТ10772, где способность первого антитела блокировать связывание второго антитела с полипептидом ТАТ10772 составляет по меньшей мере 40%, и при использовании одинаковых концентраций антител свидетельствует о том, что первое антитело обладает способностью связываться с эпитопом, с которым связывается второе антитело.
22. Способ ингибирования роста клетки, которая экспрессирует белок, имеющий аминокислотную последовательность, представленную в SEQ ID NO:2, заключающийся в том, что приводят в контакт клетку с антителом по одному из пп.1, 18 или 19, при этом связывание антитела с белком вызывает ингибирование роста указанной клетки.
23. Способ по п.22, в котором клетка представляет собой клетку рака яичника.
24. Способ терапевтического лечения млекопитающего, которое имеет злокачественную опухоль, содержащую клетки, которые экспрессируют белок, имеющий аминокислотную последовательность, которая представлена в SEQ ID NO:2, заключающийся в том, что вводят млекопитающему в терапевтически эффективном количестве антитело по одному из пп.1, 18 или 19, осуществляя тем самым эффективное лечение млекопитающего.
25. Способ по п.4, в котором злокачественная опухоль представляет собой опухоль яичника.
26. Способ определения присутствия белка ТАТ10772 в образце, в котором предполагается присутствие указанного белка, заключающийся в том, что обрабатывают образец антителом по одному из пп.1, 18 или 19 и определяют связывание антитела с белком в образце, где связывание антитела с белком свидетельствует о присутствии указанного белка в образце.
27. Способ по п.26, в котором образец содержит клетку, которая, как предполагается, экспрессирует указанный белок.
28. Способ по п.27, в котором клетка представляет собой клетку рака яичника.
29. Способ по п.26, в котором антитело несет обнаруживаемую метку.
30. Способ диагностики присутствия опухоли у млекопитающего, заключающийся в том, что определяют уровень экспрессии гена, кодирующего белок, который имеет аминокислотную последовательность, представленную в SEQ ID NO:2, в тест-образце клеток ткани, полученных из организма млекопитающего, и в контрольном образце клеток, полученных из такой же ткани, для которых известно, что они являются здоровыми, где более высокий уровень экспрессии указанного белка в тест-образце по сравнению с контрольным образцом свидетельствует о присутствии опухоли у млекопитающего, из организма которого получен тест-образец.
31. Способ по п.30, в котором стадия определения уровня экспрессии гена, кодирующего указанный белок, заключается в применении олигонуклеотида в гибридизации in situ или РВ-ПЦР-анализе.
32. Способ по п.30, в котором стадия определения уровня экспрессии гена, кодирующего указанный белок, заключается в применении антитела в иммуногистохимическом анализе или анализе методом Вестерн-блоттинга.
33. Способ по п.30, в котором опухоль представляет собой опухоль яичника, молочной железы или поджелудочной железы.
34. Способ диагностического выявления опухоли у млекопитающего, заключающийся в том, что приводят в контакт тест-образец клеток ткани, полученных из организма млекопитающего, с антителом по одному из пп.1, 18 или 19 и выявляют образование комплекса между антителом и белком ТАТ10772 в тест-образце, где образование комплекса свидетельствует о присутствии опухоли в организме млекопитающего.
35. Способ по п.34, в котором тест-образец клеток ткани получают из организма индивидуума, у которого предполагается наличие злокачественной опухоли.
36. Способ по п.35, в котором злокачественная опухоль представляет собой опухоль яичника, молочной железы или поджелудочной железы.
RU2008101365/10A 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли RU2430112C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69209205P 2005-06-20 2005-06-20
US60/692,092 2005-06-20
US79395106P 2006-04-21 2006-04-21
US60/793,951 2006-04-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2009136946/10A Division RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Publications (2)

Publication Number Publication Date
RU2008101365A true RU2008101365A (ru) 2009-07-27
RU2430112C2 RU2430112C2 (ru) 2011-09-27

Family

ID=37595671

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008101365/10A RU2430112C2 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли
RU2009136946/10A RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009136946/10A RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Country Status (23)

Country Link
US (8) US7989595B2 (ru)
EP (2) EP1910419A2 (ru)
JP (2) JP5196654B2 (ru)
KR (3) KR100970824B1 (ru)
CN (1) CN101948541B (ru)
AT (1) ATE523525T1 (ru)
AU (2) AU2006262603B2 (ru)
BR (2) BRPI0622254A2 (ru)
CA (1) CA2611778C (ru)
CR (2) CR9672A (ru)
DK (1) DK2135881T3 (ru)
EC (1) ECSP088122A (ru)
ES (1) ES2373080T3 (ru)
IL (1) IL187343A (ru)
MA (1) MA29615B1 (ru)
MX (1) MX2007016322A (ru)
NO (1) NO20080361L (ru)
NZ (2) NZ563370A (ru)
PL (1) PL2135881T3 (ru)
PT (1) PT2135881E (ru)
RU (2) RU2430112C2 (ru)
SG (1) SG155947A1 (ru)
WO (1) WO2007001851A2 (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
CA2677925A1 (en) 2007-03-02 2008-09-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Improvement of protein production comprising increasing the expression or activity of cert
AR066476A1 (es) * 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
KR101486615B1 (ko) 2007-07-16 2015-01-28 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
RU2553566C2 (ru) 2008-01-31 2015-06-20 Дженентек, Инк. АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2020201002B2 (en) * 2008-06-25 2022-04-07 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
KR102284435B1 (ko) * 2008-06-25 2021-08-02 노바르티스 아게 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
EP3858854A1 (en) 2008-06-25 2021-08-04 Novartis AG Stable and soluble antibodies inhibiting tnf
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
AU2013203004C1 (en) * 2008-06-25 2022-01-20 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
CN104788564A (zh) 2009-03-25 2015-07-22 健泰科生物技术公司 抗-fgfr3抗体及其使用方法
KR20120003478A (ko) * 2009-04-01 2012-01-10 제넨테크, 인크. 항-ＦｃＲＨ5 항체 및 면역접합체 및 사용 방법
SG175332A1 (en) 2009-05-05 2011-11-28 Boehringer Ingelheim Int Cho / cert cell lines
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CN103755809B (zh) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
PT2552959T (pt) * 2010-03-26 2017-04-21 Memorial Sloan Kettering Cancer Center Anticorpos para muc16 e métodos de utilização dos mesmos
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
MX339666B (es) 2010-06-24 2016-06-03 Genentech Inc * Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CN102585010A (zh) * 2011-01-16 2012-07-18 董贵俊 一种检测重组人碱性成纤维细胞生长因子(rhbFGF)的免疫胶乳微球及其制备方法
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MX379256B (es) * 2013-03-15 2025-03-10 Regeneron Pharma Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
KR101502680B1 (ko) * 2013-04-01 2015-03-17 중앙대학교 산학협력단 난소과립종양세포 진단용 펩타이드 및 이의 용도
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
WO2016049214A1 (en) 2014-09-23 2016-03-31 Genentech, Inc. METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
BR112017008666A2 (pt) 2014-11-05 2018-01-30 Genentech, Inc. anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
CN105675735B (zh) * 2014-11-19 2018-07-17 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
WO2016160615A1 (en) 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
FI3310814T3 (fi) 2015-06-16 2023-09-21 Hoffmann La Roche HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3482205A1 (en) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
EP3580241A4 (en) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTI-FACTOR D ANTIBODIES AND USES OF THESE LATEST
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3642231A4 (en) * 2017-06-22 2021-06-23 Apexigen, Inc. ANTI-VISTA ANTIBODIES AND METHODS OF USE
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
CN108181214B (zh) * 2018-02-09 2020-06-30 北京爱泰浦生物医药科技有限责任公司 使用atap肽治疗疾病的方法和组合物
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
CN112533957A (zh) 2018-06-04 2021-03-19 普瑞赛格恩公司 Muc16特异性嵌合抗原受体及其用途
BR112021003416A2 (pt) 2018-08-30 2021-05-18 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr usando proteínas de fusão
TWI888359B (zh) 2018-09-11 2025-07-01 瑞士商赫孚孟拉羅股份公司 噻吩并－三唑并－二氮呯醋酸酯
TWI856084B (zh) 2019-04-01 2024-09-21 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
CN109988086B (zh) * 2019-04-04 2021-06-18 三峡大学 一种小分子抑制剂azin30及其在制药中的应用
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN120584135A (zh) 2022-11-10 2025-09-02 英姆维亚公司 结合dr5和muc16的细胞毒性双特异性抗体及其用途
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
KR20000070989A (ko) * 1997-02-12 2000-11-25 나가야마 오사무 임파구계 종양의 치료제
EP1787999B1 (en) * 1997-04-07 2010-08-04 Genentech, Inc. Anti-VEGF antibodies
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002344326A1 (en) * 2001-05-11 2002-11-25 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2491017A1 (en) 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
BR0315270A (pt) * 2002-10-16 2005-08-30 Euro Celtique Sa Anticorpo isolado ou um fraguemento de anticorpo que se liga a antìgeno, anticorpo monoclonal, hibridona, molécula de ácido nucleico isolada, composição farmacêutica, artigo de fabricação, polipeptìdeo de fusão e métodos para melhorar um sintoma de um distúrbio relacionado com o ca125/0772p e para ajudar na identificação de um anticorpo ou fragmento de anticorpo que se liga a antìgeno
CA2505919A1 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Arkansas Ca125 gene and its use for diagnostic and therapeutic interventions
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
DK1725249T3 (en) * 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
ATE452147T1 (de) 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
US8404803B2 (en) 2005-03-31 2013-03-26 Chugai Seiyaku Kabushiki Kaisha Cancer-associated antigen analogue peptides and uses thereof
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados

Also Published As

Publication number Publication date
WO2007001851A3 (en) 2007-03-22
SG155947A1 (en) 2009-10-29
CR20130455A (es) 2013-10-22
CA2611778C (en) 2012-11-27
JP2012188449A (ja) 2012-10-04
ES2373080T3 (es) 2012-01-31
AU2006262603A1 (en) 2007-01-04
US7989595B2 (en) 2011-08-02
NZ563370A (en) 2010-10-29
CN101948541B (zh) 2014-08-06
IL187343A0 (en) 2008-04-13
AU2006262603B2 (en) 2011-01-06
RU2423382C1 (ru) 2011-07-10
US20110177103A1 (en) 2011-07-21
HK1134098A1 (en) 2010-04-16
EP2135881A1 (en) 2009-12-23
EP2135881B1 (en) 2011-09-07
KR100970824B1 (ko) 2010-07-16
US20160296634A1 (en) 2016-10-13
US20140314794A1 (en) 2014-10-23
KR101103108B1 (ko) 2012-01-04
JP2008546780A (ja) 2008-12-25
KR20080017104A (ko) 2008-02-25
MX2007016322A (es) 2008-04-07
ECSP088122A (es) 2008-02-20
NZ583206A (en) 2011-07-29
US20120114673A1 (en) 2012-05-10
BRPI0613382A8 (pt) 2018-01-02
DK2135881T3 (da) 2011-12-05
BRPI0613382A2 (pt) 2010-06-29
US20140205616A1 (en) 2014-07-24
IL187343A (en) 2012-02-29
RU2009136946A (ru) 2011-04-20
KR20100084706A (ko) 2010-07-27
PT2135881E (pt) 2011-12-21
US20090041749A1 (en) 2009-02-12
US8449883B2 (en) 2013-05-28
US20140050744A1 (en) 2014-02-20
ATE523525T1 (de) 2011-09-15
AU2010251794A1 (en) 2011-01-13
CR9672A (es) 2008-07-31
CN101948541A (zh) 2011-01-19
US20180344864A1 (en) 2018-12-06
MA29615B1 (fr) 2008-07-01
NO20080361L (no) 2008-03-25
WO2007001851A2 (en) 2007-01-04
JP5196654B2 (ja) 2013-05-15
CA2611778A1 (en) 2007-01-04
BRPI0622254A2 (pt) 2011-08-09
KR20090101980A (ko) 2009-09-29
RU2430112C2 (ru) 2011-09-27
EP1910419A2 (en) 2008-04-16
PL2135881T3 (pl) 2012-02-29

Similar Documents

Publication Publication Date Title
RU2008101365A (ru) Композиции и способы диагностики и лечения опухоли
JP5631733B2 (ja) 抗ＥｐＣＡＭ抗体およびその使用
CN113527489A (zh) 抗cd73的抗体及其用途
RU2012140451A (ru) Композиции и способы для диагностики и лечения опухолей
JP2008546780A5 (ru)
AU2013302620B2 (en) Stem cell enhancing therapeutics
CN109422811A (zh) 抗cd47抗体及其用途
RU2656153C1 (ru) Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
CN107001452B (zh) 用于治疗癌症的抗ck8抗体
EP1648506B1 (en) Method for treating synovial sarcoma
CA2936346A1 (en) Antibody targeting cell surface deposited complement protein c3d and use thereof
CN113906053B (zh) 抗cea抗体及其应用
RU2012151492A (ru) Композиции и способы для диагностики и лечения опухоли
RU2016148616A (ru) Анти-lgr5 антитела и их применение
CN103130896B (zh) 抗细胞表面异位表达的单克隆抗体及其制备方法和用途
WO2016052756A1 (ja) 浸潤能の高い癌細胞の検出用又は診断用試薬
CN113597432B (zh) 抗EpCAM抗体及其应用
CN113801231A (zh) 抗dog-1抗体或其抗原结合片段及其用途
CN102786598B (zh) 抗ercc1 单克隆抗体4f9 及其用途
WO2023227115A1 (en) A method of treating solid tumor
AU2022246948A9 (en) Il-38-specific antibodies
HK40064841A (en) Anti-cea antibody and application thereof
CN117677396A (zh) Il-38特异性抗体
CN102786597A (zh) 抗ercc1单克隆抗体2e12及其用途
HK1148536B (en) Anti-epcam antibody and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190615